CRISPR screen identifies Zika-fighting gene

Mosquito
UT Southwestern researchers used CRISPR screening to identify a gene that helps cells resist viruses like Zika, which is spread by mosquitoes. (auimeesri/iStock/Getty Images Plus/Getty Images)

The gene editing system CRISPR is being widely adopted as a tool for genome-scale screening. Now researchers at the University of Texas Southwestern Medical Center are reporting that they successfully used CRISPR to pinpoint a gene that helps human cells resist infection from flaviviruses like Zika.

They did it by knocking out every gene in the genome one at a time and then examining how cells respond to flavivirus infection. The gene IFI6 gene emerged as a potent inhibitor, the team reported in the journal Nature Microbiology.

The scientists' approach centered around a cytokine called interferon, which plays an important role in cells’ response against pathogens. These proteins are released once a virus has been detected, setting off an alarm to other cells so that they can prepare a defense by inducing the transcription of interferon-stimulated genes.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

“In the CRISPR screen, we used human liver cells and knocked out every gene in the genome—about 19,000 genes—one at a time. We then stimulated the cells with interferon, knowing that this stimulation would normally allow the cells to resist viral infection," explained John Schoggins, assistant professor of microbiology and leader of the team, in a release. "For the cells that did not resist infection—because they were missing a gene due to the CRISPR knockout—we used next-generation sequencing to figure out the identity of the relevant genes.”

Cells with the IFI6 gene showed robust inhibition of yellow fever, dengue, Zika and West Nile viruses, said Schoggins, while the IFI6-knockout lines were notably susceptible to infections.

RELATED: New ideas for improving the development of drugs and vaccines targeting Zika

Because flaviviruses can cause serious symptoms—Zika, for example, has been linked to neurological defects in infants—scientists have been looking for different ways to tackle them. Researchers at Albert Einstein College of Medicine and Pennsylvania State University recently found the RSAD2 gene could naturally create a compound that’s effective against Zika. According to researchers at the Washington University School of Medicine in St. Louis, the widely known malaria drug hydroxychloroquine can block the transmission of Zika to the fetus because it suppresses a waste-management process in cells called autophagy.

Previous studies used CRISPR screening to identify genes that give rise to flavivirus infection, and a Broad Institute-led team has also created a sensitive Zika diagnostic based on the gene-editing technology.

The UT Southwestern researchers hope their study can also serve as a foundation for developing therapies against flavivirus. That said, additional studies would need to be done to show whether CRISPR screens in other cell types would yield the same result. For instance, studying neurons would be helpful for unlocking clues to Zika, but the team will have to figure out how to get around logistical challenges that CRISPR screening in brain cells presents, he said.

Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.